Is it time to repurpose geroprotective diabetes medications for prevention of dementia?
作者信息
He Diana, Aleksic Sandra
机构信息
Department of Internal Medicine, Montefiore Medical Center, Bronx, New York, USA.
Department of Internal Medicine, Divisions of Endocrinology and Geriatrics, Albert Einstein College of Medicine, Bronx, New York, USA.
出版信息
J Am Geriatr Soc. 2023 Jul;71(7):2041-2045. doi: 10.1111/jgs.18405. Epub 2023 May 25.
Abstract
摘要
相似文献
1
Is it time to repurpose geroprotective diabetes medications for prevention of dementia?
J Am Geriatr Soc. 2023 Jul;71(7):2041-2045. doi: 10.1111/jgs.18405. Epub 2023 May 25.
2
Diabetes Therapies for Dementia.
Curr Neurol Neurosci Rep. 2019 Jul 12;19(8):58. doi: 10.1007/s11910-019-0973-4.
3
Study to investigate cognitive function in type 2 diabetes.
AWHONN Lifelines. 2002 Feb-Mar;6(1):16-7. doi: 10.1111/j.1552-6356.2002.tb00011.x.
4
Metformin protects against dementia in diabetes.
Nat Rev Neurol. 2023 Dec;19(12):711. doi: 10.1038/s41582-023-00900-4.
5
Neuroprotective properties of DPP-4i: A therapeutic target for dementia prevention in elderly diabetic patients?
J Diabetes Investig. 2023 Apr;14(4):525-527. doi: 10.1111/jdi.13972. Epub 2023 Jan 8.
6
Changes in Medication Use After Dementia Diagnosis in an Observational Cohort of Individuals with Diabetes Mellitus.
J Am Geriatr Soc. 2017 Jan;65(1):77-82. doi: 10.1111/jgs.14429. Epub 2016 Sep 19.
7
Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.
CNS Drugs. 2019 Feb;33(2):143-160. doi: 10.1007/s40263-018-0601-x.
8
Call for effective therapies for preventing dementia in people with type 2 diabetes.
Lancet Diabetes Endocrinol. 2024 Aug;12(8):510-513. doi: 10.1016/S2213-8587(24)00158-X. Epub 2024 Jun 17.
9
Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus.
J Diabetes Investig. 2016 Jan;7(1):5-16. doi: 10.1111/jdi.12420. Epub 2015 Oct 3.
10
The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study.
J Alzheimers Dis. 2021;81(3):1263-1272. doi: 10.3233/JAD-201535.
引用本文的文献
1
Heterogeneous treatment effects of GLP-1RAs and SGLT2is on risk of Alzheimer's disease and related dementia in patients with type 2 diabetes: Insights from a real-world target trial emulation.
Alzheimers Dement. 2025 Jun;21(6):e70313. doi: 10.1002/alz.70313.
2
Glycated hemoglobin and body mass index as mediators of GLP-1RAs and Alzheimer's disease and related dementias in patients with type 2 diabetes.
Alzheimers Dement. 2025 Apr;21(4):e70161. doi: 10.1002/alz.70161.
3
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias.
JAMA Neurol. 2025 May 1;82(5):439-449. doi: 10.1001/jamaneurol.2025.0353.
4
Trends in Co-morbid Dementia and Chronic Kidney Disease.
J Gen Intern Med. 2025 Jan 14. doi: 10.1007/s11606-024-09069-y.
5
Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study.
BMJ. 2024 Aug 28;386:e079475. doi: 10.1136/bmj-2024-079475.
6
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.
Mov Disord. 2024 Nov;39(11):1960-1970. doi: 10.1002/mds.29992. Epub 2024 Aug 27.
本文引用的文献
1
Onset age of diabetes and incident dementia: A prospective cohort study.
J Affect Disord. 2023 May 15;329:493-499. doi: 10.1016/j.jad.2023.02.138. Epub 2023 Mar 2.
2
Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.
J Am Geriatr Soc. 2023 Jul;71(7):2096-2106. doi: 10.1111/jgs.18306. Epub 2023 Feb 23.
3
Association of Race and Ethnicity With Incidence of Dementia Among Older Adults.
JAMA. 2022 Apr 19;327(15):1488-1495. doi: 10.1001/jama.2022.3550.
4
Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
Diabetes Care. 2022 Feb 1;45(2):372-380. doi: 10.2337/dc21-1815.
5
Neuroprotective Effect of SGLT2 Inhibitors.
Molecules. 2021 Nov 28;26(23):7213. doi: 10.3390/molecules26237213.
6
IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.
Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6.
7
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24.
8
Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US.
JAMA Netw Open. 2021 Apr 1;4(4):e216139. doi: 10.1001/jamanetworkopen.2021.6139.
9
Dapagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
10
Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study.
Diabetes Care. 2020 Nov;43(11):2691-2701. doi: 10.2337/dc20-0892. Epub 2020 Sep 23.
Zotero 插件